1. The characterization of psychotic symptoms in succinic semialdehyde dehydrogenase deficiency: a review.
- Author
-
Colijn MA
- Subjects
- Adolescent, Age of Onset, Aggression, Amino Acid Metabolism, Inborn Errors epidemiology, Amino Acid Metabolism, Inborn Errors genetics, Amino Acid Metabolism, Inborn Errors therapy, Anticonvulsants therapeutic use, Anxiety Disorders genetics, Child, Contraindications, Drug, Developmental Disabilities epidemiology, Developmental Disabilities genetics, Developmental Disabilities therapy, Electroencephalography, Epilepsy genetics, Humans, Neuroimaging, Phenotype, Psychotropic Drugs therapeutic use, Sleep Disorders, Intrinsic genetics, Succinate-Semialdehyde Dehydrogenase antagonists & inhibitors, Succinate-Semialdehyde Dehydrogenase genetics, Symptom Assessment, Valproic Acid adverse effects, Valproic Acid pharmacology, gamma-Aminobutyric Acid metabolism, Amino Acid Metabolism, Inborn Errors psychology, Developmental Disabilities psychology, Hallucinations genetics, Psychotic Disorders genetics, Succinate-Semialdehyde Dehydrogenase deficiency
- Abstract
Succinic semialdehyde dehydrogenase (SSADH) deficiency is an ultra-rare inborn error of metabolism that results in disrupted gamma-amino butyric acid (GABA) catabolism. In addition to developmental delay, intellectual disability, hypotonia, ataxia, and seizures, a variety of neuropsychiatric symptoms may occur, including psychosis. By highlighting all available and relevant case reports/series, this qualitative review seeks to characterize the prevalence, clinical manifestation, pathophysiology, and treatment of psychotic symptoms in this population. Psychosis occurs in a minority of SSADH-deficient individuals, and most commonly presents as auditory or visual hallucinations with an onset in adolescence or young adulthood. Although the pathophysiology underlying the development of psychosis in this context is not fully understood, it likely in part relates to increased GABA and/or gamma hydroxybutyric acid activity. Although antipsychotic medications should be used cautiously in SSADH deficiency, they may be effective at treating emergent psychotic symptoms.
- Published
- 2020
- Full Text
- View/download PDF